Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder

Abstract

The effectiveness of antidepressants shows high interindividual variability ranging from full symptomatologic remission to treatment-resistant depression. Many factors can determine the variation in the clinical response, but a fundamental role is played by genetic variation within the genes encoding for the enzymes most involved in the metabolism of antidepressant drugs: the CYP2D6 and CYP2C19 isoforms of the cytochrome P450 system. This study is poised to clarify whether the different metabolizing phenotypes related to CYP2D6 and CYP2C19 could have an impact on the clinical efficacy of antidepressants and whether the frequency of these phenotypes of metabolization shows differences in the population of Sardinian patients compared to other Caucasian populations. The sample is being recruited from patients followed-up and treated at the Psychiatric Unit of the

Prescriber Adoption of SLCO1B1Genotype‐Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program

“…[5][6][7] Though the effectiveness of these strategies and tools have been previously reported with certain medications (e.g., clopidogrel, opioids, and antidepressants), to date, few implementation programs have evaluated pharmacogenetic-guided statin therapy. [8][9][10] Statins are the mainstay of treatment for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD). 11 Statins inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, which is the rate limiting factor in hepatic cholesterol production.…”

“…Such strategies include integration of genetic information into electronic health records (EHRs) to enable point‐of‐care clinical decision support (CDS), stakeholder educational materials, peer‐reviewed guidelines, and other valuable resources 5–7 . Though the effectiveness of these strategies and tools have been previously reported with certain medications (e.g., clopidogrel, opioids, and antidepressants), to date, few implementation programs have evaluated pharmacogenetic‐guided statin therapy 8–10 …”